Background: Type 1 Diabetes (T1D) has a higher incidence in low density areas but only 1.8% of US pediatric endocrinologists are located in rural areas. The telemedicine expansion (TE) that accompanied the COVID-19 pandemic presents a novel opportunity to increase access to care for rural-residing children with T1D who may live a great distance from their provider.

Purpose: The study objective was to compare trends in visit frequency amongst our region's pediatric T1D population before and after TE by those living <100 miles versus ≥100 miles from clinic (MFC) and those residing in urban versus rural areas.

Methods: We evaluated EHR data from 790 children receiving care between July 2018 - December 2021. We estimated differences in likelihood of adequately-timed monitoring care (ATMC) over time by patient CCS status using Generalized Estimating Equations.

Results: Just prior to TE, those living ≥100 MFC were 20.6% less likely to receive ATMC compared to those living <100 MFC (RR 0.79; 95% CI: 0.57, 1.11). Following TE, likelihood of ATMC decreased from 31.0% to 24.0% in those living ≥100 MFC and decreased from 39.0% to 25.9% in those living <100 MFC; decreases in ATMC for those living ≥100 MFC were less than for those living <100 MFC (RR of interaction: 1.17; 95% CI: 0.68, 2.00). Just prior to TE, those living in rural areas were 0.1% less likely to receive ATMC (RR 1.00; 95% CI: 0.61, 1.63) compared to those living in urban areas. Following TE, likelihood of ATMC decreased from 37.2% to 20.2% in those living in rural areas and decreased from 37.3% to 25.7% in those living in urban areas; decreases in ATMC were greater for those living in rural areas versus urban areas (RR of interaction: 0.79; 95% CI: 0.31, 2.01).

Conclusions: Between July 2020 and December 2021, the likelihood of ATMC decreased across the entire pediatric T1D population. Decreases in ATMC were more substantial for those living <100 MFC and/or in rural areas, however, these discrepancies were not statistically significant.

Disclosure

E.S.Mitchell: None. S.B.Andrea: Research Support; Eli Lilly and Company. I.Guttmann-bauman: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.